Pharmaceutical composition for improving skin, hair or nail quality deteriorated with iron deficiency anemia

Abstract

An object of the present disclosure is to provide a pharmaceutical composition for improving skin quality, hair quality, or nail quality that deteriorates with iron deficiency anemia.SOLUTION: The pharmaceutical composition for improving skin quality, hair quality or nail quality deteriorated with iron deficiency anemia contains (A) soluble ferric pyrophosphate and (B) at least three or more kinds of vitamins.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present disclosure relates to pharmaceutical compositions used to improve skin, hair, or nail quality that deteriorates with iron deficiency anemia. [Background technology]

[0002] Anemia is a general term for a condition characterized by a decrease in peripheral blood hemoglobin concentration. There are various types of anemia, including iron deficiency anemia, megaloblastic anemia, hemolytic anemia, renal anemia, and aplastic anemia. In Japan, iron deficiency anemia accounts for approximately 70% of anemia cases. Iron deficiency anemia is more prevalent among women, particularly those who are pregnant or breastfeeding. Iron deficiency anemia typically manifests with paleness, fatigue, shortness of breath, dizziness, palpitations, and headaches. It can also worsen skin, hair, and nail quality, resulting in dry and rough skin, dry and damaged hair, hair loss, and spoon nails (a condition in which nails become spoon-shaped and brittle and prone to cracking).

[0003] Conventionally, oral iron preparations such as soluble ferric pyrophosphate have been used to treat iron deficiency anemia. In addition to oral iron preparations, it has been reported that the ingestion of Bifidobacterium bacteria is effective in preventing or treating iron deficiency anemia (Patent Document 1), and that specific flavans, flavonones, and flavones are effective in improving iron deficiency anemia (Patent Document 2). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2011 / 114916 [Patent Document 2] Japanese Patent Application Publication No. 2019-147772 Summary of the Invention [Problem to be solved by the invention]

[0005] The deterioration of skin, hair, or nail quality associated with iron deficiency anemia is a factor that reduces quality of life (QOL). However, as shown in Comparative Example 1 below, oral iron preparations that have conventionally been used as therapeutic agents for iron deficiency anemia cannot sufficiently improve the deterioration of skin, hair, or nail quality associated with iron deficiency anemia.

[0006] Therefore, an objective of the present disclosure is to provide a pharmaceutical composition for improving the quality of skin, hair, or nails that deteriorates due to iron deficiency anemia. [Means for solving the problem]

[0007] The present inventors have conducted extensive research to solve the above-mentioned problems and have found that a pharmaceutical composition containing a combination of soluble ferric pyrophosphate and three or more vitamins can effectively improve the quality of skin, hair, or nails that deteriorates with iron deficiency anemia. The present disclosure was completed based on this finding and further research.

[0008] That is, the present disclosure provides the inventions of the following aspects. Item 1. A pharmaceutical composition for improving skin quality, hair quality, or nail quality that deteriorates due to iron deficiency anemia, comprising: The pharmaceutical composition contains (A) soluble ferric pyrophosphate and (B) at least three kinds of vitamins. Item 2. The (B) vitamins are vitamin B9, vitamin B 12 Item 1. The pharmaceutical composition according to Item 1, wherein the vitamins are at least three or more selected from the group consisting of vitamins of the 20th century, vitamin C, and vitamin E. Item 3. The pharmaceutical composition according to Item 1 or 2, wherein the vitamins (B) are at least three or more selected from the group consisting of folic acid, cyanocobalamin, tocopherol acetate, and ascorbic acid. Item 4. The pharmaceutical composition according to any one of Items 1 to 3, wherein the total amount of component (B) is 10 to 500 parts by weight per 100 parts by weight of component (A). Item 5. The pharmaceutical composition according to any one of Items 1 to 4, which is in the form of a capsule, tablet, or granule. Item 6. The pharmaceutical composition according to any one of Items 1 to 5, wherein the skin conditions that worsen due to iron deficiency anemia include rough skin, dull complexion, poor makeup application, or dark circles under the eyes. Item 7. The pharmaceutical composition according to any one of Items 1 to 6, wherein the hair quality that deteriorates due to iron deficiency anemia is dryness, coarseness, damage, frizz, or hair loss. Item 8. The pharmaceutical composition according to any one of Items 1 to 7, wherein the nail quality deterioration associated with iron deficiency anemia is nail deformation, nail discoloration, nail cracking, or the development of lines on the nail. Item 9. Use of a composition containing (A) soluble ferric pyrophosphate and (B) at least three vitamins for the manufacture of a pharmaceutical composition for improving skin, hair, or nail quality that deteriorates due to iron deficiency anemia. Item 10. A method for improving skin, hair, or nail quality that deteriorates with iron deficiency anemia, comprising administering to a person in need thereof a pharmaceutical composition containing (A) soluble ferric pyrophosphate and (B) at least three or more vitamins. Item 11. A composition containing (A) soluble ferric pyrophosphate and (B) at least three vitamins, for use in the treatment of improving skin, hair, or nail quality that deteriorates due to iron deficiency anemia. [Effects of the Invention]

[0009] According to the pharmaceutical composition of the present disclosure, by using (A) soluble ferric pyrophosphate in combination with (B) at least three or more vitamins, the synergistic effect of these compounds can produce a significantly significant improvement effect on the quality of skin, hair, or nails that deteriorates with iron deficiency anemia. DETAILED DESCRIPTION OF THE INVENTION

[0010] The pharmaceutical composition of the present disclosure is a pharmaceutical composition for improving skin, hair, or nail quality that deteriorates with iron deficiency anemia, and is characterized by containing (A) soluble ferric pyrophosphate and (B) at least three or more vitamins. In the pharmaceutical composition of the present disclosure, the synergistic effect of the soluble ferric pyrophosphate and the three or more vitamins results in a significantly more pronounced improvement in skin, hair, or nail quality that deteriorates with iron deficiency anemia. The pharmaceutical composition of the present disclosure is described in detail below.

[0011] In the present disclosure, the expression "X to Y" regarding a numerical range refers to a numerical range of X or more and Y or less.

[0012] [(A) Soluble ferric pyrophosphate] The pharmaceutical composition of the present disclosure contains soluble ferric pyrophosphate (sometimes referred to as component (A)). Soluble ferric pyrophosphate is also known as ferric pyrophosphate citrate, and is a compound known by CAS number: 1332-96-3.

[0013] The content of component (A) in the pharmaceutical composition of the present disclosure may be appropriately set depending on the dosage form and dosage of the pharmaceutical composition, and may be, for example, 1 to 40% by weight, preferably 2 to 35% by weight, more preferably 5 to 30% by weight, and even more preferably 10 to 20% by weight.

[0014] [(B) Vitamins] The pharmaceutical composition of the present disclosure contains at least three kinds of vitamins. The vitamins used in the present disclosure can be either water-soluble or fat-soluble vitamins. Examples of vitamins used in the present disclosure include water-soluble vitamins such as vitamin B and vitamin C; fat-soluble vitamins such as vitamin A, vitamin D, vitamin E, and vitamin K, including vitamin A, vitamin D, vitamin E, and vitamin K.

[0015] The B vitamins include vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, and vitamin B 12Examples of vitamin B1 include dibenzoylthiamine, dibenzoylthiamine hydrochloride, thiamine hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, thiamine monophosphate ester, thiamine diphosphate ester, thiamine diphosphate ester hydrochloride, thiamine triphosphate ester, and thiamine triphosphate ester monophosphate. Examples of vitamin B2 include riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate, riboflavin tetrabutyrate, riboflavin 5'-phosphate sodium, riboflavin tetranicotinate, and salts thereof (sodium salt, potassium salt, etc.). Examples of vitamin B3 include nicotinic acid, nicotinamide, and salts thereof (sodium salt, potassium salt, etc.). Specific examples of vitamin B5 include pantothenic acid, calcium pantothenate, sodium pantothenate, pantethine, pantetheine, pantothenyl alcohol, pantothenyl ethyl ether, pantetheine pantothenyl alcohol, etc. Specific examples of vitamin B6 include pyridoxine hydrochloride, pyridoxine acetate, pyridoxal hydrochloride, 5'-pyridoxal phosphate, and pyridoxamine hydrochloride, etc. Specific examples of vitamin B7 include biotin, etc. Specific examples of vitamin B9 include folic acid, etc. Vitamin B 12 Specific examples of the class include cyanocobalamin, methylcobalamin, hydroxocobalamin, deoxyadenosylcobalamin, adenosylcobalamin, hydroxocobalamin hydrochloride, and hydroxocobalamin acetate.

[0016] Specific examples of vitamin C include ascorbic acid, salts of ascorbic acid (sodium salt, potassium salt, etc.), ascorbyl stearate, L-ascorbyl dipalmitate, ascorbyl tetraisopalmitate dehydroascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and ascorbyl glucoside.

[0017] Specific examples of vitamin A include retinol, retinol acetate, retinol palmitate, retinal, retinoic acid, methyl retinoate, ethyl retinoate, retinol retinoate, d-δ-tocopheryl retinoate, α-tocopheryl retinoate, and β-tocopheryl retinoate.

[0018] Specific examples of vitamin D include methylhesperidin, ergocalciferol, and cholecalciferol.

[0019] Specific examples of vitamin E include tocopherol (d-, l-, or dl-form), tocopherol acetate (α-, β-, γ-, or δ-form), tocopherol nicotinate (α-, β-, γ-, or δ-form), and tocopherol succinate (α-, β-, γ-, or δ-form).

[0020] Specific examples of vitamin K include phylloquinone and falnoquinone.

[0021] The pharmaceutical composition of the present disclosure may contain three or more types of vitamins, but from the viewpoint of more effectively improving the quality of skin, hair, or nails that deteriorates with iron deficiency anemia, it is preferable that the pharmaceutical composition of the present disclosure contain four or more types of vitamins.

[0022] The specific combination of vitamins is not particularly limited, but from the viewpoint of more effectively improving the quality of skin, hair, or nails that deteriorates due to iron deficiency anemia, it is preferable to use three or more of vitamin B, vitamin C, and vitamin E; more preferably, it is preferable to use three or more of vitamin B, vitamin B 12 More preferably, three or more of folic acid, cyanocobalamin, tocopherol acetate, and ascorbic acid are used; and particularly preferably, a combination of folic acid, cyanocobalamin, tocopherol acetate, and ascorbic acid is used.

[0023] In the pharmaceutical composition of the present disclosure, the vitamins include vitamin B9, vitamin B 12 When vitamin B9, vitamin C, and vitamin E are used in combination, the ratio of these is not particularly limited. For example, 1 part by weight of vitamin B9 can be used. 12 0.001 to 1 part by weight of vitamin B9, 1 to 1000 parts by weight of vitamin C, and 0.2 to 200 parts by weight of vitamin E; preferably, 1 part by weight of vitamin B9, 0.2 to 200 parts by weight of vitamin B 12 0.005 to 0.2 parts by weight of vitamin B9, 5 to 200 parts by weight of vitamin C, and 1 to 40 parts by weight of vitamin E; more preferably, 1 part by weight of vitamin B9, 0.005 to 0.2 parts by weight of vitamin B9, 5 to 200 parts by weight of vitamin C, and 1 to 40 parts by weight of vitamin E; 12 Examples of the amount of vitamin C include 0.025 to 0.1 parts by weight of vitamin C class, 25 to 100 parts by weight of vitamin C class, and 5 to 20 parts by weight of vitamin E class.

[0024] In the pharmaceutical composition of the present disclosure, the ratio of component (A) to component (B) is not particularly limited, but examples thereof include a total amount of component (B) of 10 to 500 parts by weight, preferably 20 to 200 parts by weight, and more preferably 50 to 100 parts by weight per 100 parts by weight of component (A).

[0025] The content of component (B) in the pharmaceutical composition of the present disclosure may be appropriately set depending on the type of component (B) used, the ratio of component (A) to component (B), the dosage form and administration amount of the pharmaceutical composition, and the like, and may be, for example, 1 to 40 wt %, preferably 2 to 30 wt %, more preferably 5 to 20 wt %, and even more preferably 7 to 15 wt % of the total amount of component (B).

[0026] More specifically, the (B) component includes vitamin B9, vitamin B 12 When vitamins of the type, vitamin C, and vitamin E are used in combination, the content of component (B) in the pharmaceutical composition of the present disclosure may be in the following ranges. Vitamin B 9 kind : 0.01 to 8% by weight, preferably 0.05 to 4% by weight, more preferably 0.1 to 0.4% by weight. Vitamin B 12 kind : 0.0001 to 0.5% by weight, preferably 0.002 to 0.2% by weight, more preferably 0.004 to 0.02% by weight. Vitamin C : 0.1 to 39% by weight, preferably 2 to 18% by weight, more preferably 5 to 14% by weight. Vitamin E : 0.01 to 20% by weight, preferably 0.1 to 8% by weight, more preferably 0.5 to 4% by weight.

[0027] [Other ingredients] The pharmaceutical composition of the present disclosure may contain other nutritional components or pharmacological components in addition to the components described above. Such nutritional components or pharmacological components are not particularly limited as long as they are usable in oral pharmaceuticals, and examples thereof include amino acids, minerals, carbohydrates, fatty acids, plant extracts, antioxidants, etc. These components may be used alone or in combination of two or more. The content of these components is appropriately determined depending on the type of component used, the dosage form of the pharmaceutical composition, the dosage, etc.

[0028] Furthermore, the pharmaceutical composition of the present disclosure may contain, as necessary, bases and additives in addition to the aforementioned components in order to prepare it into a desired formulation. Such bases and additives are not particularly limited as long as they are usable in oral pharmaceuticals, and examples thereof include excipients, disintegrants, lubricants, binders, thickeners, lower alcohols, solid oils, higher alcohols, water-soluble polymers, surfactants, polyhydric alcohols, pH adjusters, buffers, antioxidants, preservatives, chelating agents, and water. These may be used alone or in combination of two or more. The content of these bases and additives is appropriately determined depending on the type of ingredients used, the dosage form of the pharmaceutical composition, and the like.

[0029] [Dosage form] The dosage form of the pharmaceutical composition of the present disclosure is not particularly limited as long as it can be taken orally, and may be any of solid, semi-solid, or liquid.Specific dosage forms of the pharmaceutical composition of the present disclosure include capsules (soft capsules, hard capsules), tablets (including enteric-coated tablets, plain tablets, sugar-coated tablets, etc.), granules, powders, jellies, syrups, liquids, etc.Among these oral pharmaceuticals, capsules, tablets, and granules are preferred.

[0030] [Application] The pharmaceutical composition of the present disclosure is used to improve skin, hair, or nail quality that deteriorates due to iron deficiency anemia. Iron deficiency anemia is anemia caused by a lack of iron, which constitutes hemoglobin in red blood cells. In the present disclosure, "improvement" includes preventing the onset of symptoms, alleviating, mitigating, or curing symptoms, or slowing or stopping the progression of symptoms.

[0031] Skin conditions that worsen due to iron deficiency anemia include rough skin, dull complexion, poor makeup application, dark circles under the eyes, etc. One aspect of the pharmaceutical composition of the present disclosure is particularly suitable for use in improving rough skin or dull complexion that occurs due to iron deficiency anemia.

[0032] Hair quality problems that are associated with iron deficiency anemia include dryness, stiffness, damage, frizz, hair loss, etc. One aspect of the pharmaceutical composition of the present disclosure is particularly suitable for use in improving dryness or stiffness of hair that are associated with iron deficiency anemia.

[0033] Deterioration of nail quality associated with iron deficiency anemia includes nail deformation (such as spoon nails), discoloration of nails, cracked nails, development of nail streaks, etc. One aspect of the pharmaceutical composition of the present disclosure is particularly suitable for use in improving nail discoloration or cracked nails associated with iron deficiency anemia.

[0034] [Dosage] The dosage of the pharmaceutical composition of the present disclosure is not particularly limited and is set appropriately depending on the dosage form, the age and severity of symptoms of the recipient, etc., but for example, the daily dosage of soluble ferric pyrophosphate may be set to about 60 to 100 mg, preferably about 75 to 85 mg, and the number of times of administration per day may be set to 1 to 3 times, preferably 1 or 2 times per day. [Example]

[0035] The present disclosure will be explained in more detail below by showing examples, but it should not be construed as being limited to these examples.

[0036] 1. Capsule manufacturing The components shown in Table 1 were mixed in predetermined amounts and filled into hard capsules to obtain capsules (265 mg of content per capsule).

[0037] [Table 1]

[0038] 2. Verification of the effect of improving skin quality deteriorated due to iron deficiency anemia Thirty female subjects with iron deficiency anemia-related skin problems (rough skin, dull complexion, poor makeup application, and dark circles under the eyes) were randomly divided into three groups (Example 1, Comparative Example 1, and Comparative Example 2, 10 subjects per group) and administered the capsules once daily for four weeks, at a dose of two capsules per administration. After four weeks of administration, the subjects were asked to rate their satisfaction with the improvement in their skin problems (rough skin, dull complexion, poor makeup application, and dark circles under the eyes) on a five-point scale (satisfied, somewhat satisfied, neutral, somewhat dissatisfied, dissatisfied). The percentage of subjects who answered "satisfied" was calculated as the efficacy rate.

[0039] The results are shown in Table 2. Capsules containing soluble ferric pyrophosphate and folic acid showed almost no improvement in skin quality (Comparative Example 1). Furthermore, capsules containing four vitamins (ascorbic acid, d-α-tocopherol acetate, cyanocobalamin, and folic acid) also showed insufficient improvement in skin quality (Comparative Example 2). In contrast, capsules containing soluble ferric pyrophosphate and four vitamins (ascorbic acid, d-α-tocopherol acetate, cyanocobalamin, and folic acid) showed a significantly better improvement in skin quality than those observed in Comparative Examples 1 and 2 (Example 1). These results demonstrate that combining soluble ferric pyrophosphate with three or more vitamins effectively improves skin quality deteriorated by iron deficiency anemia through their synergistic effects.

[0040] [Table 2]

[0041] 3. Verification of the effect of improving hair and nail quality that deteriorates due to iron deficiency anemia Eight female subjects with poor hair and nail quality due to iron deficiency anemia (dry hair, rough hair, discolored nails, cracked nails) were randomly divided into three groups (Example 1, Comparative Example 1, and Comparative Example 2, two subjects per group) and given the capsules once a day, two capsules per day, for four weeks.

[0042] Both subjects who took the capsules of Example 1 for four weeks reported improvements in dry hair, stiff hair, discoloration of nails, and brittle nails. On the other hand, no such reports were reported by subjects in the groups who took the capsules of Comparative Examples 1 and 2. These results demonstrate that combining soluble ferric pyrophosphate with three or more vitamins is effective in improving hair and nail quality that deteriorates due to iron deficiency anemia.

[0043] [External composition of the second embodiment] The present disclosure also provides topical compositions effective for treating skin diseases, as embodiments of the invention other than the pharmaceutical compositions for improving skin, hair, or nail quality that deteriorates with iron deficiency anemia. Specifically, the topical compositions are Creams A1 to A18, B1 to B18, C1 to C18, and D1 to D18 shown below.

[0044] Creams A1 to A18 and B1 to B18 were prepared according to the following method. An oil phase composition was prepared by mixing predetermined amounts of vitamin A oil or vitamin A acetate (retinol acetate), ceramide 2, stearyl alcohol, cetanol, isopropyl myristate, white petrolatum, liquid paraffin, squalane, dimethylpolysiloxane, propyl parahydroxybenzoate, polyoxyethylene hydrogenated castor oil 50, polysorbate 60, and self-emulsifying glyceryl monostearate and dissolving the mixture by heating at 75 to 85°C. Separately, an aqueous phase composition was prepared by mixing predetermined amounts of a heparinoid, allantoin, dipotassium glycyrrhizinate, propylene glycol, 1,3-butylene glycol, sodium edetate hydrate, carboxyvinyl polymer, triethanolamine, methyl parahydroxybenzoate, and purified water. Next, the aqueous phase composition heated to 80°C was gradually added to the oil phase composition heated to 80°C and mixed to perform an emulsification operation, thereby obtaining compositions for external use (creamy oil-in-water emulsion preparations). The compositions of creams A1 to A18 and B1 to B18 are as follows:

[0045] Cream A1 had the following composition: heparinoid: 0.3% by weight, allantoin: 0.2% by weight, dipotassium glycyrrhizinate: 1% by weight, ceramide 2: 0.5% by weight, vitamin A oil: appropriate amount, stearyl alcohol: 2% by weight, cetanol: 3% by weight, isopropyl myristate: 2% by weight, white petrolatum: 4% by weight, liquid paraffin: 5.5% by weight, squalane: 0.5% by weight, dimethylpolysiloxane: 0.3% by weight, propyl parahydroxybenzoate: 0.1% by weight. 0.4% by weight of polyoxyethylene hydrogenated castor oil 50, 1.7% by weight of polysorbate 60, 1.2% by weight of self-emulsifying glyceryl monostearate, 4% by weight of propylene glycol, 4% by weight of 1,3-butylene glycol, 0.1% by weight of sodium edetate hydrate, 0.2% by weight of methyl parahydroxybenzoate, 0.55% by weight of carboxyvinyl polymer, an appropriate amount of triethanolamine, and the remainder: purified water, totaling 100% by weight. The vitamin A oil used contained 1 million IU / g of retinol palmitate.

[0046] Cream A2 has the same composition as Cream A1 except that it contains 0.0001% by weight of vitamin A oil; Cream A3 has the same composition as Cream A1 except that it contains 0.0005% by weight of vitamin A oil; Cream A4 has the same composition as Cream A1 except that it contains 0.001% by weight of vitamin A oil; Cream A5 has the same composition as Cream A1 except that it contains 0.003% by weight of vitamin A oil; Cream A6 has the same composition as Cream A1 except that it contains 0.005% by weight of vitamin A oil; Cream A7 has the same composition as Cream A1 except that it contains 0.007% by weight of vitamin A oil; Cream A8 has the same composition as Cream A1 except that it contains 0.01% by weight of vitamin A oil; Cream A9 has the same composition as Cream A1 except that it contains 0.02% by weight of vitamin A oil; and Cream A10 has the same composition as Cream A1 except that it contains 0.03% by weight of vitamin A oil. Cream A11 has the same composition as Cream A1 except that it contains 0.05% by weight of vitamin A oil; Cream A12 has the same composition as Cream A1 except that it contains 0.07% by weight of vitamin A oil; Cream A13 has the same composition as Cream A1 except that it contains 0.1% by weight of vitamin A oil; Cream A14 has the same composition as Cream A1 except that it contains 0.2% by weight of vitamin A oil; Cream A15 has the same composition as Cream A1 except that it contains 0.25% by weight of vitamin A oil; Cream A16 has the same composition as Cream A1 except that it contains 0.27% by weight of vitamin A oil; Cream A17 has the same composition as Cream A1 except that it contains 0.3% by weight of vitamin A oil; and Cream A18 has the same composition as Cream A1 except that it contains 0.5% by weight of vitamin A oil.

[0047] Cream B1 had the following composition: heparinoid: 0.3% by weight, allantoin: 0.2% by weight, dipotassium glycyrrhizinate: 1% by weight, ceramide 2: 0.5% by weight, vitamin A acetate: appropriate amount, stearyl alcohol: 2% by weight, cetanol: 3% by weight, isopropyl myristate: 2% by weight, white petrolatum: 4% by weight, liquid paraffin: 5.5% by weight, squalane: 0.5% by weight, dimethylpolysiloxane: 0.3% by weight, propyl parahydroxybenzoate: 0.1% by weight. Amount %, polyoxyethylene hydrogenated castor oil 50: 0.4 wt%, polysorbate 60: 1.7 wt%, self-emulsifying glyceryl monostearate: 1.2 wt%, propylene glycol: 4 wt%, 1,3-butylene glycol: 4 wt%, sodium edetate hydrate: 0.1 wt%, methyl parahydroxybenzoate 0.2 wt%, carboxyvinyl polymer: 0.55 wt%, triethanolamine: appropriate amount, and purified water: remainder, total 100 wt%.

[0048] Cream B2 has the same composition as Cream B1 except that it contains 0.0001% by weight of vitamin A acetate; Cream B3 has the same composition as Cream B1 except that it contains 0.0005% by weight of vitamin A acetate; Cream B4 has the same composition as Cream B1 except that it contains 0.001% by weight of vitamin A acetate; Cream B5 has the same composition as Cream B1 except that it contains 0.003% by weight of vitamin A acetate; Cream B6 has the same composition as Cream B1 except that it contains 0.005% by weight of vitamin A acetate; Cream B7 has the same composition as Cream B1 except that it contains 0.007% by weight of vitamin A acetate; Cream B8 has the same composition as Cream B1 except that it contains 0.01% by weight of vitamin A acetate; Cream B9 has the same composition as Cream B1 except that it contains 0.02% by weight of vitamin A acetate; and Cream B10 has the same composition as Cream B1 except that it contains 0.02% by weight of vitamin A acetate. Cream B11 has the same composition as Cream B1 except that it contains 0.03% by weight of vitamin A acetate; Cream B11 has the same composition as Cream B1 except that it contains 0.05% by weight of vitamin A acetate; Cream B12 has the same composition as Cream B1 except that it contains 0.07% by weight of vitamin A acetate; Cream B13 has the same composition as Cream B1 except that it contains 0.1% by weight of vitamin A acetate; Cream B14 has the same composition as Cream B1 except that it contains 0.2% by weight of vitamin A acetate; Cream B15 has the same composition as Cream B1 except that it contains 0.25% by weight of vitamin A acetate; Cream B16 has the same composition as Cream B1 except that it contains 0.27% by weight of vitamin A acetate; Cream B17 has the same composition as Cream B1 except that it contains 0.3% by weight of vitamin A acetate; and Cream B18 has the same composition as Cream B1 except that it contains 0.5% by weight of vitamin A acetate.

[0049] Creams C1 to C18 and D1 to D18 were prepared according to the following method. An oil phase composition was prepared by mixing predetermined amounts of vitamin A oil or vitamin A acetate, stearyl alcohol, cetanol, isopropyl myristate, white petrolatum, liquid paraffin, squalane, dimethylpolysiloxane, propyl parahydroxybenzoate, polyoxyethylene hydrogenated castor oil 50, polysorbate 60, and self-emulsifying glyceryl monostearate and dissolving the mixture by heating at 75 to 85°C. Separately, an aqueous phase composition was prepared by mixing predetermined amounts of a heparinoid, allantoin, dipotassium glycyrrhizinate, propylene glycol, 1,3-butylene glycol, sodium edetate hydrate, carboxyvinyl polymer, triethanolamine, methyl parahydroxybenzoate, and purified water. Next, the aqueous phase composition heated to 80°C was gradually added to the oil phase composition heated to 80°C and mixed to perform an emulsification operation, thereby obtaining compositions for external use (creamy oil-in-water emulsion preparations). The compositions of creams C1 to C18 and D1 to D18 are as follows:

[0050] Cream C1 had the following composition: heparinoid: 0.3% by weight, allantoin: 0.2% by weight, dipotassium glycyrrhizinate: 1% by weight, vitamin A oil: an appropriate amount, stearyl alcohol: 2% by weight, cetanol: 3% by weight, isopropyl myristate: 2% by weight, white petrolatum: 4% by weight, liquid paraffin: 5.5% by weight, squalane: 0.5% by weight, dimethylpolysiloxane: 0.3% by weight, propyl parahydroxybenzoate: 0.1% by weight, polyoxyethylene terephthalate: 0.1% by weight, methylparaben ... The ingredients were 0.4% by weight of ethylene hydrogenated castor oil 50, 1.7% by weight of polysorbate 60, 1.2% by weight of self-emulsifying glyceryl monostearate, 4% by weight of propylene glycol, 4% by weight of 1,3-butylene glycol, 0.1% by weight of sodium edetate hydrate, 0.2% by weight of methyl parahydroxybenzoate, 0.55% by weight of carboxyvinyl polymer, an appropriate amount of triethanolamine, and the remainder was purified water, totaling 100% by weight. The vitamin A oil used contained 1 million IU / g of retinol palmitate.

[0051] Cream C2 has the same composition as Cream C1 except that it contains 0.0001% by weight of vitamin A oil; Cream C3 has the same composition as Cream C1 except that it contains 0.0005% by weight of vitamin A oil; Cream C4 has the same composition as Cream C1 except that it contains 0.001% by weight of vitamin A oil; Cream C5 has the same composition as Cream C1 except that it contains 0.003% by weight of vitamin A oil; Cream C6 has the same composition as Cream C1 except that it contains 0.005% by weight of vitamin A oil; Cream C7 has the same composition as Cream C1 except that it contains 0.007% by weight of vitamin A oil; Cream C8 has the same composition as Cream C1 except that it contains 0.01% by weight of vitamin A oil; Cream C9 has the same composition as Cream C1 except that it contains 0.02% by weight of vitamin A oil; and Cream C10 has the same composition as Cream C1 except that it contains 0.03% by weight of vitamin A oil. Cream C11 has the same composition as Cream C1 except that it contains 0.05% by weight of vitamin A oil; Cream C12 has the same composition as Cream C1 except that it contains 0.07% by weight of vitamin A oil; Cream C13 has the same composition as Cream C1 except that it contains 0.1% by weight of vitamin A oil; Cream C14 has the same composition as Cream C1 except that it contains 0.2% by weight of vitamin A oil; Cream C15 has the same composition as Cream C1 except that it contains 0.25% by weight of vitamin A oil; Cream C16 has the same composition as Cream C1 except that it contains 0.27% by weight of vitamin A oil; Cream C17 has the same composition as Cream C1 except that it contains 0.3% by weight of vitamin A oil; and Cream C18 has the same composition as Cream C1 except that it contains 0.5% by weight of vitamin A oil.

[0052] Cream D1 had the following composition: heparinoid: 0.3% by weight, allantoin: 0.2% by weight, dipotassium glycyrrhizinate: 1% by weight, vitamin A acetate: an appropriate amount, stearyl alcohol: 2% by weight, cetanol: 3% by weight, isopropyl myristate: 2% by weight, white petrolatum: 4% by weight, liquid paraffin: 5.5% by weight, squalane: 0.5% by weight, dimethylpolysiloxane: 0.3% by weight, propyl parahydroxybenzoate: 0.1% by weight, polio The ingredients were: 0.4% by weight of ethylenedioxyhydrogenated castor oil 50, 1.7% by weight of polysorbate 60, 1.2% by weight of self-emulsifying glyceryl monostearate, 4% by weight of propylene glycol, 4% by weight of 1,3-butylene glycol, 0.1% by weight of sodium edetate hydrate, 0.2% by weight of methyl parahydroxybenzoate, 0.55% by weight of carboxyvinyl polymer, an appropriate amount of triethanolamine, and the remainder: purified water, totaling 100% by weight. The vitamin A oil used contained 1 million IU / g of vitamin A.

[0053] Cream D2 has the same composition as Cream D1 except that it contains 0.0001% by weight of vitamin A acetate; Cream D3 has the same composition as Cream D1 except that it contains 0.0005% by weight of vitamin A acetate; Cream D4 has the same composition as Cream D1 except that it contains 0.001% by weight of vitamin A acetate; Cream D5 has the same composition as Cream D1 except that it contains 0.003% by weight of vitamin A acetate; Cream D6 has the same composition as Cream D1 except that it contains 0.005% by weight of vitamin A acetate; Cream D7 has the same composition as Cream D1 except that it contains 0.007% by weight of vitamin A acetate; Cream D8 has the same composition as Cream D1 except that it contains 0.01% by weight of vitamin A acetate; Cream D9 has the same composition as Cream D1 except that it contains 0.02% by weight of vitamin A acetate; and Cream D10 has the same composition as Cream D1 except that it contains 0.02% by weight of vitamin A acetate. Cream D11 has the same composition as Cream D1 except that it contains 0.03% by weight of vitamin A acetate; Cream D11 has the same composition as Cream D1 except that it contains 0.05% by weight of vitamin A acetate; Cream D12 has the same composition as Cream D1 except that it contains 0.07% by weight of vitamin A acetate; Cream D13 has the same composition as Cream D1 except that it contains 0.1% by weight of vitamin A acetate; Cream D14 has the same composition as Cream D1 except that it contains 0.2% by weight of vitamin A acetate; Cream D15 has the same composition as Cream D1 except that it contains 0.25% by weight of vitamin A acetate; Cream D16 has the same composition as Cream D1 except that it contains 0.27% by weight of vitamin A acetate; Cream D17 has the same composition as Cream D1 except that it contains 0.3% by weight of vitamin A acetate; and Cream D18 has the same composition as Cream D1 except that it contains 0.5% by weight of vitamin A acetate.

[0054] Creams A1 to A18, B1 to B18, C1 to C18, and D1 to D18 are all used for preventing or treating skin diseases. Creams A1 to A18, B1 to B18, C1 to C18, and D1 to D18 all have effects according to the amounts of heparinoid, allantoin, dipotassium glycyrrhizinate, and vitamin A contained therein, and are external use compositions effective in preventing or treating skin diseases.

Claims

1. A pharmaceutical composition for improving skin quality, hair quality, or nail quality that deteriorates due to iron deficiency anemia, comprising: The pharmaceutical composition contains (A) soluble ferric pyrophosphate and (B) at least three kinds of vitamins.

2. The (B) vitamins are vitamin B 9 Vitamin B 12 2. The pharmaceutical composition according to claim 1, wherein the vitamins are at least three or more selected from the group consisting of vitamin C, vitamin B12, and vitamin E.

3. 3. The pharmaceutical composition according to claim 1, wherein the vitamins (B) are at least three or more selected from the group consisting of folic acid, cyanocobalamin, tocopherol acetate, and ascorbic acid.

4. 3. The pharmaceutical composition according to claim 1, wherein the total amount of component (B) is 10 to 500 parts by weight per 100 parts by weight of component (A).

5. 3. The pharmaceutical composition according to claim 1 or 2, which is in the form of a capsule, tablet, or granule.

Images